喉癌的分子靶向治疗  

The molecular targeted therapy of laryngeal carcinoma

作　　者：姜寰宇(综述)[1] 孙冀(审校)[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院头颈外科鼻咽喉口腔病区,哈尔滨150081

出　　处：《实用肿瘤学杂志》2013年第6期573-576,共4页Practical Oncology Journal

摘　　要：近年来，手术及放、化疗在喉癌治疗方面取得了一定进步，但是Ⅲ、Ⅳ期喉癌预后仍不乐观，所以需要新的治疗手段来提高喉癌的治疗效果。癌症的分子靶向治疗很有前景。本文对EGFR，VEGF，COX-2，mTOR，Nm23-H1，iNOS各靶点与喉癌之间的关系，以及相关抑制剂对喉癌治疗的研究进展做一综述。Despite recent advances in surgical techniques and radiotherapy and chemotherapy, the prog- nosis of laryngeal carcinoma is still poor,especially patients with in the stage III and IV. Hence,there needs a no- vel therapy to improve the treatment of laryngeal carcinoma. Molecular targeted therapy represents an exciting field in the treatment of cancer. This review focuses on the relationship between the laryngeal carcinoma and some promising targets,including EGFR, VEGF, COX - 2, roTOR, Nm23 - H1 and iNOS, and related inhibitors in la- ryngeal carcinoma research.

关 键 词：喉癌 分子靶向治疗 环氧合酶-2 哺乳动物雷帕霉素靶蛋白 诱导型一氧化氮合成酶 

分 类 号：R739.65[医药卫生—肿瘤]